SCHEMBL4167785

SCHEMBL4167785

N#Cc1ccc(Cn2cc(-c3ccco3)c(=O)[nH]c2=O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.48
ALDH1A1 P00352 4/20 0.48
MAPK1 P28482 2/20 0.48
MAPT P10636 2/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
PKM P14618 2/20 0.41
CYP2C19 P33261 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HPGD P15428 1/20 0.40
ADORA2A P29274 2/20 0.40
ADORA3 P0DMS8 1/20 0.40
ADORA2B P29275 1/20 0.40
ADORA1 P30542 1/20 0.40
GLA P06280 2/20 0.40
RECQL P46063 2/20 0.40
BLM P54132 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4158442 0.88 KDM4E (0.48) KDM4EALDH1A1MAPK1MAPTMEN1
SCHEMBL4157745 0.84 ALDH1A1 (0.54) KDM4EALDH1A1MAPK1HTTNPSR1
SCHEMBL4156367 0.77 KDM4E (0.43) KDM4EALDH1A1MAPTHTTNPSR1
SCHEMBL4172004 0.75 HPGD (0.44) MEN1KMT2AHPGDBLMCYP1A2
SCHEMBL4160559 0.74 ALDH1A1 (0.46) KDM4EALDH1A1MAPK1MAPTLMNA
SCHEMBL4174262 0.73 P2RY2 (0.44) KDM4EALDH1A1MAPTMEN1KMT2A
SCHEMBL4170112 0.68 KMT2A (0.53) KDM4EALDH1A1MAPK1MAPTLMNA
SCHEMBL3680667 0.68 KMT2A (0.46) KDM4EALDH1A1MAPK1MAPTHTT
SCHEMBL7834032 0.66 SMN1; SMN2 (0.64) KDM4EALDH1A1MAPK1HTTMEN1
SCHEMBL14892573 0.66 KDM4E (0.81) KDM4EALDH1A1MAPK1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US disclosed
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US disclosed
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US disclosed
WO-2007122634-A2 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2007-11-01 WO disclosed
WO-2007122634-A2 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS TK1, LCK, FYN KDM4E 2284/4885ALDH1A1 1813/4885MAPK1 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.